Investigating the possible neurological side effects follow the COVID-19 vaccine
DOI:
https://doi.org/10.18203/2319-2003.ijbcp20232558Keywords:
COVID 19, Vaccine, Neurological side effectsAbstract
Background: With the widespread of COVID-19 vaccination around the world, there are many case reports which referred to the neurological complications following vaccination. However, due to the lack of more information about this, especially in our country Iran, the aim of this study was to investigate the possible neurological side effects of the COVID-19 vaccine in patients.
Methods: This cross-sectional study was conducted on 1046 people injecting various types of COVID-19 vaccines, including Sinopharm, AstraZeneca, Sputnik V, CovIran-Barekat, Covaxin, SpikoGen, and PastoCovac plus, who were registered in the health system due to vaccine complications. These people were evaluated in terms of the overall incidence rate of neurological complications, types of neurological complications, and the relationship between the occurrence of neurological complications and the type of vaccine.
Results: Of all patients, 589 (56.3%) were female and 457 (43.7%) were male, and most of them were from the age group of 60 years and older (43.8%). 247 people (23.6%) had neurological complications that most of them related to the headache (16.6%).
Conclusions: The results of this study showed that the neurological side effects associated with the covid-19 vaccination were in mild level and most of them were seen in AstraZeneca vaccine and so, in line with the recommendation of the European medicines agency, the injection of this vaccine should be done with caution.
References
Shereen MA, Khan S, Kazmi A, Bashir N, Siddique R. COVID-19 infection: Emergence, transmission, and characteristics of human coronaviruses. J Adv Res. 2020;24:91-8.
Gralinski LE, Menachery VD. Return of the Coronavirus: 2019-nCoV. Viruses. 2020;12(2):135.
Wang C, Horby PW, Hayden FG, Gao GF. A novel coronavirus outbreak of global health concern. Lancet. 2020;395(10223):470-3.
Askarian M, Fu L, Taghrir MH, Borazjani R, Shayan Z, Taherifard E, et al. Factors affecting COVID-19 vaccination intent among Iranians: COVID-19 vaccination acceptance. Soc Sci Res Net. 2020;2020:1-21.
Kaur SP, Gupta V. COVID-19 Vaccine: A comprehensive status report. Virus Res. 2020;288:198114.
Le TT, Andreadakis Z, Kumar A, Román RG, Tollefsen S, Saville M, et al. The COVID-19 vaccine development landscape. Nat Rev Drug Discov. 2020; 19(5):305-6.
Basiri N, Koushki M. Study of Vaccine Production Abroad and Scientific and Research Challenges of COVID-19 Vaccine Production in Iran. Ann Roman Soc Cell Biol. 2021:17249-56.
Sprent J, King C. COVID-19 vaccine side effects: The positives about feeling bad. Science immunology. 2021;6(60):9256.
Al Khames Aga QA, Alkhaffaf WH, Hatem TH, Nassir KF, Batineh Y, Dahham AT, et al. Safety of COVID‐19 vaccines. J Med Virol. 2021;93(12):6588-94.
Finsterer J. Neurological side effects of SARS‐CoV‐2 vaccinations. Acta Neurol Scand. 2022;145(1):5-9.
Göbel CH, Heinze A, Karstedt S, Morscheck M, Tashiro L, Cirkel A, et al. Clinical characteristics of headache after vaccination against COVID-19 (coronavirus SARS-CoV-2) with the BNT162b2 mRNA vaccine: a multicentre observational cohort study. J Med Virol. 2021;3(3):169.
Ramasamy MN, Minassian AM, Ewer KJ, Flaxman AL, Folegatti PM, Owens DR, et al. Safety and immunogenicity of ChAdOx1 nCoV-19 vaccine administered in a prime-boost regimen in young and old adults (COV002): a single-blind, randomised, controlled, phase 2/3 trial. Lancet. 2020;396(10267): 1979-93.
Samimagham HR, Hassani Azad M, Hooshyar D, Arabi M, Reza Hosseini Z. Adverse Effects of Gam-COVID-Vac (Sputnik V) Vaccine. Shiraz E-Med J. 2021;22(12):116278.
García-Azorín D, Do TP, Gantenbein AR, Hansen JM, Souza MNP, Obermann M, et al. Delayed headache after COVID-19 vaccination: a red flag for vaccine induced cerebral venous thrombosis. J Headache Pain. 2021;22(1):1-5.
Pisani D, Gioacchini FM, Viola P, Scarpa A, Astorina A, Re M, et al. Audiovestibular disorders after COVID-19 vaccine: is there an association? Audiol Res. 2022;12(3):212-23.
Fallahi MJ, Esmaeilzadeh Shahri N, Khodamoradi Z, Meymandi Nia M, Sehatpour F, Mahmoudi L. Case of possible encephalopathy following receiving the first dose of Iranian COVID‐19Vaccine; COVIran Barakat. Clin Case Rep. 2022;10(4):e05661.
Khajavirad N, Salehi M, Haji GA, Khalili H, Arab Ahmadi M, Dehghan Manshadi SA, et al. Serious events following COVID‐19 vaccination with ChAdOx1 nCoV‐19 vaccine (Vaxzevria): A short case series from Iran. Clin Case Rep. 2022;10(2):e05390.
Saeed BQ, Al-Shahrabi R, Alhaj SS, Alkokhardi ZM, Adrees AO. Side effects and perceptions following Sinopharm COVID-19 vaccination. Int J Infect Dis. 2021;111:219-26.
Beatty AL, Peyser ND, Butcher XE, Cocohoba JM, Lin F, Olgin JE, et al. Analysis of COVID-19 vaccine type and adverse effects following vaccination. JAMA. 2021;4(12):e2140364.
Sriwastava S, Sharma K, Khalid SH, Bhansali S, Shrestha AK, Elkhooly M, et al. COVID-19 vaccination and neurological manifestations: a review of case reports and case series. Brain Sci. 2022;12(3): 407.
Cirillo N, Doan R. The association between COVID-19 vaccination and Bell's palsy. Lancet Infect Dis. 2022;22(1):5-6.
De Michele M, Kahan J, Berto I, Schiavo OG, Iacobucci M, Toni D, et al. Cerebrovascular complications of COVID-19 and COVID-19 vaccination. Circ Res. 2022;130(8):1187-203.
Toni EM. COVID-19 Vaccine Safety Update, VAXZEVRIA, AstraZeneca AB. Eur Med Agency. 2021.
Sahin U, Muik A, Derhovanessian E, Vogler I, Kranz LM, Vormehr M, et al. COVID-19 vaccine BNT162b1 elicits human antibody and TH1 T cell responses. Nature. 2020;586(7830):594-9.
Pozzetto B, Legros V, Djebali S, Barateau V, Guibert N, Villard M, et al. Immunogenicity and efficacy of heterologous ChAdOx1–BNT162b2 vaccination. Nature. 2021;600(7890):701-6.
Taquet M, Husain M, Geddes J, Luciano S, Harrison P. Cerebral venous thrombosis and portal vein thrombosis: A retrospective cohort study of 537,913 COVID-19 cases. Clin Med. 2021;101061:1-16.
